研究者業績

橋元 誠

ハシモト マコト  (Makoto Hashimoto)

基本情報

所属
武蔵野大学 薬学部 薬学科 准教授
学位
博士(農学)(東京農工大学大学院連合農学研究科)

J-GLOBAL ID
200901074534035987
researchmap会員ID
5000023937

委員歴

 1

論文

 10
  • Kazuki Ishikawa, Minori Hashimoto, Noriko Kusuoku, Chiharu Nozaki, Makoto Hashimoto, Koji Ichinose
    The Journal of Antibiotics 2026年6月  
  • Kosho Makino, Nanase Koizumi, Makoto Hashimoto, Koji Ichinose, Shunsuke Sueki, Tetsu Tsubogo, Masahiro Anada
    European Journal of Organic Chemistry 2025年11月24日  
  • Susumu Watari, Makoto Hashimoto, Kazuki Ishikawa, Takuya Kumamoto, Hideaki Kakeya, Koji Ichinose
    Results in Chemistry 17 102620-102620 2025年9月  
  • Makoto Hashimoto, Kazuki Ishikawa, Yuri Fukushima, Sarina Shimazu, Mizuha Yabuzaki, Yuka Kamezawa, Takaaki Taguchi, Koji Ichinose
    Chembiochem : a European journal of chemical biology e202500049 2025年3月6日  
    Actinorhodin (ACT) from Streptomyces coelicolor A3(2) is an aromatic polyketide antibiotic with a benzoisochromanequinone (BIQ) skeleton. Although actVI-ORF3 and actVI-ORF4 are not essential for ACT biosynthesis, homologous genes to these are present in the biosynthetic gene clusters of BIQ lactones. In this study, ActVI-ORF3 was identified as a cofactor-independent enzyme with lactonization activity, using ACT as a substrate. ActVI-ORF3 recognized dihydrokalafungin and 8-hydroxykalafafungin, which share the same pyran-ring configuration as ACT, but not nanaomycin A, which has an opposite configuration. In contrast, ActVI-ORF4 functioned as an NAD(P)-dependent oxidoreductase, catalyzing the delactonization of BIQ lactones. Conversion experiments using isotopically labeled compounds revealed that both lactonization and delactonization reactions of these enzymes yielded products in which the carboxyl oxygen at the C1 position was retained. Subsequently, we reexamined the accumulation of ACT-related compounds in the actVI-ORF3 and actVI-ORF-4 disruptants. The results suggested that ACT intermediates are predominantly pooled in the bacteria as (S)-DNPA rather than in lactone-form. The contribution of ActVI-ORF4 to metabolic flux is not significant, and endogenous reductases can convert these intermediates to the dihydro form, which subsequently re-enters the ACT biosynthetic pathway.
  • Makoto Hashimoto, Susumu Watari, Takaaki Taguchi, Kazuki Ishikawa, Takuya Kumamoto, Susumu Okamoto, Koji Ichinose
    Angewandte Chemie (International ed. in English) 2022年12月2日  
    A plethora of dimeric natural products exist with diverse chemical structures and biological activities. A major strategy for dimerization is aryl coupling reactions catalyzed by cytochrome P450 or laccase. Actinorhodin (ACT) from Streptomyces coelicolor has a dimeric pyranonaphthoquinone structure connected by a C-C bond. Here, we identified a NmrA-family dimerizing enzyme, ActVA-ORF4, and a cofactor independent oxidase, ActVA-ORF3, both involved in the last step of ACT biosynthesis. ActVA-ORF4 is a unique  NAD(P)H-dependent enzyme that catalyzes the inter-molecular C-C bond formation using 8-hydroxydihydrokalafungin (DHK-OH) as the sole substrate. On the other hand, ActVA-ORF3 was found to be a quinone-forming enzyme that produces the coupling substrate, DHK-OH, and the final product, ACT. Consequently, the functional assignment of all essential enzymes in ACT biosynthesis was completed, which would be a landmark in our understanding of the entire biosynthetic pathway for one of the best-known model natural products, ACT.

MISC

 13

講演・口頭発表等

 58

担当経験のある科目(授業)

 7

共同研究・競争的資金等の研究課題

 5

学術貢献活動

 2